Showing 5161-5170 of 5909 results for "".
- jCyte Enters Into Ex-US Licensing and Commercialization Agreement for jCell Therapy With Santenhttps://modernod.com/news/jcyte-enters-into-ex-us-licensing-and-commercialization-agreement-for-jcell-therapy-with-santen/2477727/jCyte Inc. announced it has entered into a licensing agreement with Santen Pharmaceutical to develop and commercialize its first-in-class, investigational therapy, jCell, outside the United States, in regions including Europe, Asia, and Japan. Under the terms of the licensing agreement, jC
- Hydroxychloroquine Fails to Help Hospitalized Coronavirus Patients in US Funded Studyhttps://modernod.com/news/hydroxychloroquine-fails-to-help-hospitalized-coronavirus-patients-in-us-funded-study/2477728/Hydroxychloroquine, a decades-old malaria drug, didn’t appear to help hospitalized patients with COVID-19, according to a new observational study published Thursday in the New England Journal of Medicine, according to a CN
- Sight Sciences Introduces the Next-Generation Omni Surgical System for Microinvasive Glaucoma Surgeryhttps://modernod.com/news/sight-sciences-introduces-the-next-generation-omni-surgical-system-for-microinvasive-glaucoma-surgery/2477720/Sight Sciences announced the launch of its next-generation Omni Surgical System for microinvasive glaucoma surgery (MIGS) procedures. The Omni Surgical System combines two distinct angle procedures—ab interno trabeculotomy and transluminal viscoelastic delivery. It is the only MIGS
- Mystery Inflammatory Syndrome In Kids And Teens Likely Linked To COVID-19https://modernod.com/news/mystery-inflammatory-syndrome-in-kids-and-teens-likely-linked-to-covid-19/2477722/Sixty-four children and teens in New York State are suspected of having a mysterious inflammatory syndrome that is believed to be linked to COVID-19, the New York Department of Health said in an alert issued Wednesday, as
- Bausch + Lomb Licenses Exclusive Rights To a Biosimilar Candidate for Lucentis (Ranibizumab) in the US and Canadahttps://modernod.com/news/bausch-lomb-licenses-exclusive-rights-to-a-biosimilar-candidate-for-lucentis-ranibizumab-in-the-us-and-canada/2477718/Bausch + Lomb has entered into an exclusive licensing agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, a Nordic biosimilar developer, to develop and commercialize a biosimilar candidate to Lucentis (ranibizumab) in the United States and Canada. The companies
- Massachusetts Eye and Ear Advancing Experimental Gene-Based COVID-19 Vaccine, AAVCOVIDhttps://modernod.com/news/massachusetts-eye-and-ear-advancing-experimental-gene-based-covid-19-vaccine-aavcovid/2477708/Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham, announced progress toward the testing and development of an experimental vaccine called AAVCOVID, a novel gene-based vaccine candidate against SARS-CoV2, the virus that causes COVID-19. The
- Adverum Biotechnologies Reports Positive Interim Data of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-reports-positive-interim-data-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477705/Adverum Biotechnologies announced new interim clinical data from Cohorts 1-3 of the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD) and provided
- Alnylam, Vir to Advance Experimental RNAi Therapeutic VIR-2703 as Potential COVID-19 Treatmenthttps://modernod.com/news/alnylam-vir-to-advance-experimental-rnai-therapeutic-vir-2703-as-potential-covid-19-treatment/2477702/Alnylam Pharmaceuticals and Vir Biotechnology announced that they plan to develop VIR-2703, an investigational RNAi therapeutic targeting the SARS-CoV-2 genome as an inhalational formulation for the potential treatment or prevention of COVID-19. “To our knowledge, this is one of the
- Studies Yield Mixed Findings for Investigational Drug Abicipar in Wet AMDhttps://modernod.com/news/studies-yield-mixed-findings-for-investigational-drug-abicipar-in-wet-amd/2477703/The investigational drug abicipar pegol is noninferior to ranibizumab for achieving stable vision in people with wet age-related macular degeneration (AMD), according to a pair of phase-3 trials, as reported by Reuters.wet Abicipar
- AAO Surveys Reveal Severe Effect COVID-19 Is Having on Ophthalmology Practiceshttps://modernod.com/news/american-academy-of-ophthalmology-releases-covid-19-survey/2477701/The American Academy of Ophthalmology (AAO) released the initial findings of a series of COVID-19 pulse surveys, which aim to reveal the pandemic’s effect on ophthalmology practices and their patients. The pulse surveys will be used to advocate for additional relief and to develop resources to he